Filing Flows

Filing Flows › Companies › Rigel Pharmaceuticals › Cash flow

Rigel Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$34.6M in Q3 2026 · $89.9M over twelve months

Operating cash flow$34.6M
Free cash flow+$34.6M
Cash / net income2.6×
Cash conversion cycle127 days

Analysis

In Q3 2026, Rigel Pharmaceuticals generated $34.6M of operating cash flow. That is $10.5M more than in Q3 2025 ($24.0M).

Over the twelve months to Sep 30, 2026, operating cash flow was $89.9M; the largest uses were net borrowing (+) / repaid (−) ($62.8M), other investing ($34.3M), other financing ($2.6M); besides operations, cash came from shares issued ($7.9M); the cash balance fell by $1.9M.

Operating cash flow was $34.6M against net income of $13.2M — 2.6× profit, cash ran ahead of reported earnings. The largest differences: payables +$4.9M, stock-based pay +$4.9M, inventory −$4.2M.

Its cash conversion cycle was 127 days (receivables 64 + inventory 129 − payables 66).

Free cash flow

Rigel Pharmaceuticals: free cash flow by quarterRigel Pharmaceuticals: free cash flow by quarter$14.5MQ4 2024−$893KQ1 2025$30.5MQ2 2025$24.0MQ3 2025$22.0MQ4 2025$2.7MQ1 2026$30.7MQ2 2026$34.6MQ3 2026
Operating cash flow less capital spending.
Rigel Pharmaceuticals: operating cash flow against capital spendingRigel Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$14.5M$0Q4 2024−$893K$0Q1 2025$30.5M$0Q2 2025$24.0M$0Q3 2025$22.0M$0Q4 2025$2.7M$0Q1 2026$30.7M$0Q2 2026$34.6M$0Q3 2026
Latest (Q3 2026): Operating cash flow $34.6M, Capital spending $0.

Capital allocation, year by year

Rigel Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearRigel Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow $5.9MFY2021: Shares issued $4.8MFY2021: Capital spending −$627K$10.7MFY2021FY2022: Operating cash flow −$73.8MFY2022: Net borrowing $19.5MFY2022: Shares issued $2.1MFY2022: Asset sales $893KFY2022: Capital spending −$450K$22.6MFY2022FY2023: Operating cash flow −$5.7MFY2023: Net borrowing $19.9MFY2023: Shares issued $1.0MFY2023: Asset sales $259K$21.3MFY2023FY2024: Operating cash flow $31.5MFY2024: Shares issued $2.0MFY2024: Asset sales $98K$33.5MFY2024FY2025: Operating cash flow $75.7MFY2025: Net borrowing −$7.5MFY2025: Shares issued $8.1M$83.8MFY2025
Over these 5 years operating cash flow totalled $33.5M; the largest uses were operating cash flow ($79.5M) and net borrowing ($7.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$99.3M
Debt$45.0M
Net cash$54.3M
Due within a year$7.5M

Rigel Pharmaceuticals funds itself: free cash flow was $89.9M over the last twelve months, and $99.3M of cash and investments stands against $45.0M of debt ($7.5M due within a year, 13.2× covered by cash).

Rigel Pharmaceuticals: debt maturities by year (FY2024)Rigel Pharmaceuticals: debt maturities by year (FY2024)$7.5MYear 1$30.0MYear 2$22.5MYear 3
Principal due in each year as disclosed in the annual report, against $99.3M of cash and investments now.

Where the cash came from and went

Rigel Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Rigel Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$34.6MOther financing−$32.0MOther investing−$18.4MCash drawn (+) / kept (−)$14.2MShares issued$2.8MBuybacks−$1.0M
Rigel Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Rigel Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$89.9MNet borrowing (+) / repaid (−)−$62.8MOther investing−$34.3MShares issued$7.9MOther financing−$2.6MCash drawn (+) / kept (−)$1.9M

From profit to cash

Rigel Pharmaceuticals: net income to operating cash flow, Q3 2026Rigel Pharmaceuticals: net income to operating cash flow, Q3 2026Net income$13.2MDepreciation & amortization$1.8MStock-based pay$4.9MDeferred taxes$3.5MReceivables−$417KInventory−$4.2MPayables$4.9MAccrued liabilities$3.1MEmployee-related liabilities$1.5MPrepaid and other assets$2.8MOperating cash flow$34.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20266412966127
Q2 20266113945155
Q1 202678226114190
Q4 20256419285171
Q3 202557230108179
Q2 20253615211475
Q1 20257010974105
Q4 202458865787

Every quarter

QuarterOperating cash flowBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$34.6M−$1.0M—$2.8M$14.2M$34.6M
Q2 2026$30.7M−$511K−$47.8M$1.9M−$36.4M$30.7M
Q1 2026$2.7M−$3.7M−$7.5M$321K$16.2M$2.7M
Q4 2025$22.0M—−$7.5M$2.9M$8.0M$22.0M
Q3 2025$24.0M——$4.3M$4.9M$24.0M
Q2 2025$30.5M——$418K−$7.7M$30.5M
Q1 2025−$893K——$484K$11.0M−$893K
Q4 2024$14.5M——$1.5M−$5.1M$14.5M

Rigel Pharmaceuticals: income statement and cash flow

Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%. The chart follows the revenue to costs, profit and cash.

Rigel Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.